171 related articles for article (PubMed ID: 32642717)
1. Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice.
Qin Y; Musket A; Kou J; Preiszner J; Tschida BR; Qin A; Land CA; Staal B; Kang L; Tanner K; Jiang Y; Schweitzer JB; Largaespada DA; Xie Q
Neurooncol Adv; 2020; 2(1):vdaa067. PubMed ID: 32642717
[TBL] [Abstract][Full Text] [Related]
2. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous development of intratumoral heterogeneity in a transposon-induced mouse model of glioma.
Sumiyoshi K; Koso H; Watanabe S
Cancer Sci; 2018 May; 109(5):1513-1523. PubMed ID: 29575648
[TBL] [Abstract][Full Text] [Related]
4. Targeting MET for glioma therapy.
Awad AJ; Burns TC; Zhang Y; Abounader R
Neurosurg Focus; 2014 Dec; 37(6):E10. PubMed ID: 25434379
[TBL] [Abstract][Full Text] [Related]
5. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
7. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
9. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
10. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas.
Lamszus K; Laterra J; Westphal M; Rosen EM
Int J Dev Neurosci; 1999; 17(5-6):517-30. PubMed ID: 10571413
[TBL] [Abstract][Full Text] [Related]
11. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
12. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
13. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
15. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
16. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY
Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861
[TBL] [Abstract][Full Text] [Related]
17. Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors.
Francone TD; Landmann RG; Chen CT; Sun MY; Kuntz EJ; Zeng Z; Dematteo RP; Paty PB; Weiser MR
Mol Cancer Ther; 2007 Apr; 6(4):1460-6. PubMed ID: 17431125
[TBL] [Abstract][Full Text] [Related]
18. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
19. Modulation of motility and proliferation of glioma cells by hepatocyte growth factor.
Yamamoto S; Wakimoto H; Aoyagi M; Hirakawa K; Hamada H
Jpn J Cancer Res; 1997 Jun; 88(6):564-77. PubMed ID: 9263534
[TBL] [Abstract][Full Text] [Related]
20. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
